The link between intravitreal antivascular endothelial growth factor injections and glaucoma

Current Opinion in Ophthalmology

Volumn 25, Issue 2, 2014, Pages 127-133

  Soohoo, Jeffrey R ^a   Seibold, Leonard K ^a   Kahook, Malik Y ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

antivascular endothelial growth factor; glaucoma; intraocular pressure

Indexed keywords

ANGIOGENESIS INHIBITORS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; RISK ASSESSMENT; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84894066897     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000036     Document Type: Review

References (69)

1. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151:887-895; e881.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
4. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574-584. (Pubitemid 24285965)
5. Tripathi RC, Borisuth NS, Li J, Tripathi BJ. Growth factors in the aqueous humor and their clinical significance. J Glaucoma 1994;3:248-258. (Pubitemid 24267872)
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487. (Pubitemid 24356306)
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
8. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-544. (Pubitemid 29446822)
9. Andreoli CM, Miller JW. Antivascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-508. (Pubitemid 351339405)
10. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
11. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112; e1101.
12. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-324; e311.
13. Wang H, Sun X, Liu K, Xu X. Intravitreal ranibizumab (Lucentis) for the treatment of diabetic macular edema: a systematic review and metaanalysis of randomized clinical control trials. Curr Eye Res 2012;37:661-670.
14. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802-809.
15. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
16. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-1665.
17. SooHoo JR, Seibold LK, Kahook MY. Recent advances in the management of neovascular glaucoma. Semin Ophthalmol 2013;28:165-172.
18. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol 2013;7:1257-1267.
19. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-437; e427.
20. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013;97:278-284.
21. Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013;131:139-145.
22. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398.
23. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-1267.
24. Group VISiONCT. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001; e1006.
25. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-1611.
26. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
27. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
28. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 2007;27:1044-1047. (Pubitemid 350304005)
29. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118:1098-1106.
30. Frenkel RE, Haji SA, La M, et al. A protocol for the retina surgeon's safe initial intravitreal injections. Clin Ophthalmol 2010;4:1279-1285.
31. Kotliar K, Maier M, Bauer S, et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007;85:777-781. (Pubitemid 47616796)
32. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009;23:181-185.
33. Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18:658-661.
34. Cacciamani A, Oddone F, Parravano M, et al. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 2013;57:63-67.
35. Goktas A, Goktas S, Atas M, et al. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure. Cutan Ocul Toxicol 2013;32:23-26.
36. Knip MM, Valimaki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 2012;90:254-258.
37. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811.
38. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressurelowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 2010;128:1523-1527.
39. Kim KS, Jee D. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique. Jpn J Ophthalmol 2011;55:632-637.
40. Bakri SJ, Moshfeghi DM, Rundle A, et al. IOP in Eyes Treated with Monthly Ranibizumab: A Post Hoc Analysis of Data from the MARINA and ANCHOR Trials. Paper presented at the AAO Annual Meeting, October 15, 2010, Chicago, IL 2010.
41. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond) 2007;21:1541.
42. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-958.
43. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293-295.
44. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-110.
45. Loukianou E, Brouzas D, Apostolopoulos M. Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab. Int Ophthalmol 2011;31:211-213.
46. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
47. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 2010;4:28-29.
48. Martel JN, Han Y, Lin SC. Severe intraocular pressure fluctuation after intravitreal antivascular endothelial growth factor injection. Ophthalmic Surg Lasers Imaging 2011;42:e100-102; Online:e100-102.
49. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011;31:1028-1035.
50. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21:241-247. This retrospective review reports 25 eyes of patients undergoing treatment with intravitreal anti-VEGF agents who developed a sustained increase in IOP. Of note, two patients had improvement in IOP after they were changed from a fixed treatment interval to OCT-guided variable treatment intervals.
51. Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250:1435-1440. This retrospective review reports 22 eyes of patients receiving anti-VEGF treatment with bevacizumab monotherapy who developed sustained elevation in IOP. The authors noted that an interval between injections of less than 8 weeks and male sex were the risk factors for chronic IOP elevation.
52. Skalicky SE, Ho I, Agar A, Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 2012;43:328-334.
53. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
54. Wehrli SJ, Tawse K, Levin MH, et al. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 2012;32:1295-1301.
55. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008;28:996-1001.
56. Chantelau E, Berger M, Bohlken B. Silicone oil released from disposable insulin syringes. Diabetes Care 1986;9:672-673. (Pubitemid 17208949)
57. Baldwin RN. Contamination of insulin by silicone oil: a potential hazard of plastic insulin syringes. Diabet Med 1988;5:789-790.
58. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30:887-892.
59. Liu L, Ammar DA, Ross LA, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023-1034.
60. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-462.
61. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:779-781.
62. Schwartz A. Chronic open-angle glaucoma secondary to rhegmatogenous retinal detachment. Trans Am Ophthalmol Soc 1972;70:178-189.
63. Weber AJ, Zelenak D. Experimental glaucoma in the primate induced by latex microspheres. J Neurosci Methods 2001;111:39-48. (Pubitemid 33733533)
64. Kernt M, Welge-Lussen U, Yu A, et al. [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells]. Ophthalmologe 2007;104:965-971.
65. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 2010;19:437-441.
66. Perkumas KM, Stamer WD. Protein markers and differentiation in culture for Schlemm's canal endothelial cells. Exp Eye Res 2012;96:82-87.
67. Battista SA, Lu Z, Hofmann S, et al. Reduction of the available area for aqueous humor outflow and increase in meshwork herniations into collector channels following acute IOP elevation in bovine eyes. Invest Ophthalmol Vis Sci 2008;49:5346-5352.
68. Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal antivascular endothelial growth factor injections. Ophthalmology 2012;119:321-326.
69. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal antivascular endothelial growth factor therapy. Retina 2013;33:179-187. This retrospective review reported 32 eyes of 328 patients who developed sustained IOP elevation after chronic treatment with ranibizumab or bevacizumab for neovascular AMD. An increased number of intravitreal anti-VEGF injections was an independent risk factor for persistent IOP elevation.